I'll take it, but...today's movement shows you there's more interest in a small HIV drug than in pipeline assets that could be worth 20x that. I know Palinc is still a big HIV-drug-growth champion, but this shows that there are probably more shareholders still in THTX for the HIV franchise than for NASH or oncology. Admitedly, those are both still hopes and have huge discounts around them, but it is interesting to see how "the market" still perceives the company.